IDE approval provides important validation of clinical development plans for the Icellator2
GERMANTOWN, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, announces it has been granted Investigational Device Exemption (IDE) approval by the United States Food and Drug... More